Compare Quest Diagnostics Inc (DGX) vs Vanguard S&P 500 Growth Index Fund ETF (VOOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Vanguard S&P 500 Growth Index Fund ETF — how do they compare? Quest Diagnostics Inc trades at $237.51 (market cap $26.21B), while Vanguard S&P 500 Growth Index Fund ETF trades at $85.05. The key difference: Quest Diagnostics Inc pays a 1.45% dividend while Vanguard S&P 500 Growth Index Fund ETF pays none. Which is the better fit depends on your goals.
| DGX | VOOG | |
|---|---|---|
Market Cap | $26.21B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $238.50 | $85.42 |
52-Week Low | $173.49 | $65.32 |
Enterprise Value | $31.97B | — |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
VOOG trades at $85.05, down 0.18% on the day but near 52-week highs, with a bullish technical signal from moving averages and a neutral oscillator stance. Recent news highlights institutional accumulation and strong growth ETF comparisons, though RSI levels suggest potential overbought conditions. The fund focuses on large-cap growth stocks with low expense ratios, benefiting from tech sector leadership.
Outlook remains positive due to institutional inflows and growth exposure, but risks include tech concentration and market volatility. The fund's low costs and historical performance support long-term growth appeal, though investors should monitor valuation metrics amid elevated levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Vanguard S&P 500 Growth Index Fund ETF
VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →
